Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ELANE | P08246 | 2/20 | 0.59 |
| ▸ | NEK2 | P51955 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436725 | 0.92 | ELANE (0.53) | KDM4ECYP2C19ELANENEK2KMT2A | |
| SCHEMBL3436393 | 0.87 | KDM4E (0.66) | KDM4ECYP2C19ELANENEK2KMT2A | |
| SCHEMBL2421306 | 0.84 | MALT1 (0.70) | KDM4ECYP2C19NEK2KMT2AMALT1 | |
| SCHEMBL3594750 | 0.82 | MAPT (0.59) | KDM4ECYP2C19KMT2AMALT1ALDH1A1 | |
| SCHEMBL4879872 | 0.82 | KDM4E (0.60) | KDM4ECYP2C19ELANENEK2KMT2A | |
| SCHEMBL4524152 | 0.82 | NEK2 (0.67) | KDM4ECYP2C19ELANENEK2KMT2A | |
| SCHEMBL239605 | 0.82 | MALT1 (0.61) | KDM4ECYP2C19ELANENEK2KMT2A | |
| SCHEMBL3436511 | 0.81 | SMO (0.53) | KDM4EKMT2AMALT1RECQLTRPV1 | |
| SCHEMBL3436628 | 0.81 | HSD11B1 (0.49) | KDM4EELANEKMT2AMALT1RECQL | |
| SCHEMBL3436582 | 0.81 | POLB (0.52) | KMT2AMALT1TRPV1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2401279-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | Vantia Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A9 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097576-A1 | 1, 4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | VANTIA LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2009005-A1 | AZOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312941-A1 | 1,4-DISUBSTITUTED PIPERIDINES AS VASOPRESSIN RECEPTOR VIA ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | KDM4E 2389/4885CYP2C19 1165/4885ELANE 1943/4885 |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | KDM4E 1834/4885CYP2C19 1395/4885ELANE 2732/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | KDM4E 2664/4885CYP2C19 2800/4885ELANE 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.